# Eloxx Pharmaceuticals Announces Publication of Phase 2a Exaluren Data in Nonsense Mutation Alport Syndrome in the Journal of Clinical Investigation

- Source: PR Newswire M&A
- Published: 2026-11-18T21:05:00+00:00
- Category: Business
- Original: https://www.prnewswire.com/news-releases/eloxx-pharmaceuticals-announces-publication-of-phase-2a-exaluren-data-in-nonsense-mutation-alport-syndrome-in-the-journal-of-clinical-investigation-302944390.html
- Canonical: https://groundlevelnews.com/story/eloxx-pharmaceuticals-announces-publication-of-phase-2a-exaluren-data--4e0bf1/

First-in-human evidence of exaluren-mediated readthrough of collagen IV in patients with nonsense mutation Alport syndrome Kidney biopsies showed increased collagen IV abundance and partially improved podocyte morphology in all three participants Exaluren was well tolerated, with no...

_Ground Level News shows a short summary only; the full article and all rights belong to PR Newswire M&A._
